Cargando…

Broad-spectrum receptor tyrosine kinase inhibitors overcome de novo and acquired modes of resistance to EGFR-targeted therapies in colorectal cancer

It is increasingly appreciated that 3D cultures are more predictive of in vivo therapeutic efficacy than 2D cultures. Using in vitro 3D type I collagen cultures of human colorectal cancer (CRC) cell line HCA-7 derivatives CC, SC, and CC-CR, we previously identified that activation of receptor tyrosi...

Descripción completa

Detalles Bibliográficos
Autores principales: Graves-Deal, Ramona, Bogatcheva, Galina, Rehman, Saba, Lu, Yuanyuan, Higginbotham, James N., Singh, Bhuminder
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407678/
https://www.ncbi.nlm.nih.gov/pubmed/30863492
http://dx.doi.org/10.18632/oncotarget.26663
_version_ 1783401608408727552
author Graves-Deal, Ramona
Bogatcheva, Galina
Rehman, Saba
Lu, Yuanyuan
Higginbotham, James N.
Singh, Bhuminder
author_facet Graves-Deal, Ramona
Bogatcheva, Galina
Rehman, Saba
Lu, Yuanyuan
Higginbotham, James N.
Singh, Bhuminder
author_sort Graves-Deal, Ramona
collection PubMed
description It is increasingly appreciated that 3D cultures are more predictive of in vivo therapeutic efficacy than 2D cultures. Using in vitro 3D type I collagen cultures of human colorectal cancer (CRC) cell line HCA-7 derivatives CC, SC, and CC-CR, we previously identified that activation of receptor tyrosine kinases (RTKs) MET and RON contributed to resistance to the EGF receptor (EGFR)-directed therapeutic antibody cetuximab. The de novo mode of cetuximab resistance in SC cells could be overcome by crizotinib, a multi-RTK inhibitor that also targets MET and RON. We now show that crizotinib also overcomes acquired cetuximab resistance in CC-CR cells. Phospho-RTK array analysis showed increased phosphorylation of several RTKs, including MET and RON, in SC and CC-CR cells compared to cetuximab-sensitive CC counterparts. Furthermore, other multi-RTK inhibitors cabozantinib and BMS-777607 helped overcome cetuximab resistance, as measured by 3D colony growth and activation state of key signaling molecules. Conversely, addition of RTK ligands HGF and NRG1 induced cetuximab resistance in CC cells, which could be blocked by addition of crizotinib. We further determined the mechanism of the cooperative effect of cetuximab and crizotinib by FACS analysis and observed increased cell cycle arrest in G1 phase in cetuximab-resistant CRC 3D cultures. Finally, we show that crizotinib overcomes cetuximab resistance in vivo in SC nude mice xenografts. Thus, our work shows that multi-RTK inhibition strategy is a potent, broadly applicable strategy to overcome resistance to EGFR-targeted therapeutics in CRC and highlights the relevance of 3D cultures in these studies. Statement of implication: Using in vitro 3D CRC cultures and in vivo CRC xenografts, we show that parallel inhibition of multiple RTKs with small molecule inhibitors overcomes de novo and acquired resistance to EGFR-directed therapies in CRC.
format Online
Article
Text
id pubmed-6407678
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-64076782019-03-12 Broad-spectrum receptor tyrosine kinase inhibitors overcome de novo and acquired modes of resistance to EGFR-targeted therapies in colorectal cancer Graves-Deal, Ramona Bogatcheva, Galina Rehman, Saba Lu, Yuanyuan Higginbotham, James N. Singh, Bhuminder Oncotarget Research Paper It is increasingly appreciated that 3D cultures are more predictive of in vivo therapeutic efficacy than 2D cultures. Using in vitro 3D type I collagen cultures of human colorectal cancer (CRC) cell line HCA-7 derivatives CC, SC, and CC-CR, we previously identified that activation of receptor tyrosine kinases (RTKs) MET and RON contributed to resistance to the EGF receptor (EGFR)-directed therapeutic antibody cetuximab. The de novo mode of cetuximab resistance in SC cells could be overcome by crizotinib, a multi-RTK inhibitor that also targets MET and RON. We now show that crizotinib also overcomes acquired cetuximab resistance in CC-CR cells. Phospho-RTK array analysis showed increased phosphorylation of several RTKs, including MET and RON, in SC and CC-CR cells compared to cetuximab-sensitive CC counterparts. Furthermore, other multi-RTK inhibitors cabozantinib and BMS-777607 helped overcome cetuximab resistance, as measured by 3D colony growth and activation state of key signaling molecules. Conversely, addition of RTK ligands HGF and NRG1 induced cetuximab resistance in CC cells, which could be blocked by addition of crizotinib. We further determined the mechanism of the cooperative effect of cetuximab and crizotinib by FACS analysis and observed increased cell cycle arrest in G1 phase in cetuximab-resistant CRC 3D cultures. Finally, we show that crizotinib overcomes cetuximab resistance in vivo in SC nude mice xenografts. Thus, our work shows that multi-RTK inhibition strategy is a potent, broadly applicable strategy to overcome resistance to EGFR-targeted therapeutics in CRC and highlights the relevance of 3D cultures in these studies. Statement of implication: Using in vitro 3D CRC cultures and in vivo CRC xenografts, we show that parallel inhibition of multiple RTKs with small molecule inhibitors overcomes de novo and acquired resistance to EGFR-directed therapies in CRC. Impact Journals LLC 2019-02-12 /pmc/articles/PMC6407678/ /pubmed/30863492 http://dx.doi.org/10.18632/oncotarget.26663 Text en Copyright: © 2019 Graves-Deal et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Graves-Deal, Ramona
Bogatcheva, Galina
Rehman, Saba
Lu, Yuanyuan
Higginbotham, James N.
Singh, Bhuminder
Broad-spectrum receptor tyrosine kinase inhibitors overcome de novo and acquired modes of resistance to EGFR-targeted therapies in colorectal cancer
title Broad-spectrum receptor tyrosine kinase inhibitors overcome de novo and acquired modes of resistance to EGFR-targeted therapies in colorectal cancer
title_full Broad-spectrum receptor tyrosine kinase inhibitors overcome de novo and acquired modes of resistance to EGFR-targeted therapies in colorectal cancer
title_fullStr Broad-spectrum receptor tyrosine kinase inhibitors overcome de novo and acquired modes of resistance to EGFR-targeted therapies in colorectal cancer
title_full_unstemmed Broad-spectrum receptor tyrosine kinase inhibitors overcome de novo and acquired modes of resistance to EGFR-targeted therapies in colorectal cancer
title_short Broad-spectrum receptor tyrosine kinase inhibitors overcome de novo and acquired modes of resistance to EGFR-targeted therapies in colorectal cancer
title_sort broad-spectrum receptor tyrosine kinase inhibitors overcome de novo and acquired modes of resistance to egfr-targeted therapies in colorectal cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407678/
https://www.ncbi.nlm.nih.gov/pubmed/30863492
http://dx.doi.org/10.18632/oncotarget.26663
work_keys_str_mv AT gravesdealramona broadspectrumreceptortyrosinekinaseinhibitorsovercomedenovoandacquiredmodesofresistancetoegfrtargetedtherapiesincolorectalcancer
AT bogatchevagalina broadspectrumreceptortyrosinekinaseinhibitorsovercomedenovoandacquiredmodesofresistancetoegfrtargetedtherapiesincolorectalcancer
AT rehmansaba broadspectrumreceptortyrosinekinaseinhibitorsovercomedenovoandacquiredmodesofresistancetoegfrtargetedtherapiesincolorectalcancer
AT luyuanyuan broadspectrumreceptortyrosinekinaseinhibitorsovercomedenovoandacquiredmodesofresistancetoegfrtargetedtherapiesincolorectalcancer
AT higginbothamjamesn broadspectrumreceptortyrosinekinaseinhibitorsovercomedenovoandacquiredmodesofresistancetoegfrtargetedtherapiesincolorectalcancer
AT singhbhuminder broadspectrumreceptortyrosinekinaseinhibitorsovercomedenovoandacquiredmodesofresistancetoegfrtargetedtherapiesincolorectalcancer